These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38035770)

  • 1. Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms.
    Stankeviciute L; Blackman J; Tort-Colet N; Fernández-Arcos A; Sánchez-Benavides G; Suárez-Calvet M; Iranzo Á; Molinuevo JL; Gispert JD; Coulthard E; Grau-Rivera O
    J Sleep Res; 2024 Aug; 33(4):e14108. PubMed ID: 38035770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum.
    Banning LCP; Ramakers IHGB; Köhler S; Bron EE; Verhey FRJ; de Deyn PP; Claassen JAHR; Koek HL; Middelkoop HAM; van der Flier WM; van der Lugt A; Aalten P; ;
    Am J Geriatr Psychiatry; 2020 Jul; 28(7):735-744. PubMed ID: 32088096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
    van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
    JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer's continuum.
    Jiang J; Zhuo Z; Wang A; Li W; Jiang S; Duan Y; Ren Q; Zhao M; Wang L; Yang S; Awan MUN; Liu Y; Xu J
    Alzheimers Res Ther; 2024 Jul; 16(1):149. PubMed ID: 38961406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course.
    Liguori C; Placidi F; Izzi F; Spanetta M; Mercuri NB; Di Pucchio A
    Alzheimers Res Ther; 2020 Jan; 12(1):5. PubMed ID: 31901236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
    Hohman TJ; Bell SP; Jefferson AL;
    JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for ordering of Alzheimer disease biomarkers.
    Jack CR; Vemuri P; Wiste HJ; Weigand SD; Aisen PS; Trojanowski JQ; Shaw LM; Bernstein MA; Petersen RC; Weiner MW; Knopman DS;
    Arch Neurol; 2011 Dec; 68(12):1526-35. PubMed ID: 21825215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
    Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
    J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
    Zhang H; Lyu D; Jia J;
    J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
    Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
    Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.